Articles by Roger L. Williams - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Roger L. Williams

Roger L. Williams


Articles
Inside USP: Positioned for Growth
June 2, 2010

USP membership meeting prepared the standards-setting body to meet modern challenges.

Inside USP: Heparin Monographs Further Revised
March 2, 2009

USP's Stage 2 heparin monograph revisions address identification, potency, and impurities.

Inside USP: USP Metals Testing: A Workshop Report
November 2, 2008

Attendees at a recent workshop endorsed new methods to detect metals in drugs, dietary supplements, and food ingredients.

Inside USP: US Pharmacopeia Guideline for Pending Monographs
August 2, 2008

USP's guideline for pending monographs can speed up publication of monograhs and time to market.

Variability of USP Lot P Prednisone Reference Standard Tablets
June 2, 2008

The authors demonstrate that anecdotal reports of prednisone tablet variability are inaccurate.

Inside USP: Annual Scientific Meeting Recap
November 2, 2007

Representatives from 17 nations sit down to decide upon standards-setting initiatives.

Inside USP: Revising USP General Notices
August 2, 2007

USP is revising key documents to make them easier to use.

Dissolution Testing and Metrological Measurement of Quality for Solid Oral Dosage Forms
May 2, 2007

USP applies metrological principles to the dissolution procedure alone and in collaborative studies to understand and minimize potential sources of variability.

USP's Work Plan and New Revision Approaches
October 2, 2006

Efforts to solicit new monographs have fallen behind the rate of NDA approvals, while analytical techniques have become outdated because of advances in analytical technologies.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FindPharma Custom Search
Click here